Skip to main content
. 2017 Nov 2;12(11):e0187526. doi: 10.1371/journal.pone.0187526

Table 2. Results of subgroup analyses.

p Recovery ratios Number of studies (n) I2 across groups
Complete mucosal recovery
Children vs. adults <0.01* 0.65 (0.44–0.85) vs. 0.24 (0.15–0.33) 7 vs. 8 99.0%
Strict vs. non-strict/uncertain gluten-free diet 0.39 0.47 (0.24–0.70) vs. 0.33 (0.23–0.45) 12 vs. 26 95.6%
Strict adherence with at least 12-month gluten-free diet vs. others 0.32 0.44 (0.26–0.64) vs. 0.33 (0.23–0.44) 10 vs. 27 95.7%
Patients followed up for 12 months vs. others 0.70 0.38 (0.28–0.48) vs. 0.36 (0.27–0.45) 7 vs. 30 98.3%
Length of gluten-free diet
(high vs. low risk)
0.91 0.34 (0.20–0.52) vs. 0.33 (0.24–0.44) 10 vs. 27 95.0%
Assessment of adherence
(high vs. low vs. uncertain risk)
0.25 0.62 (0.27–0.88) vs. 0.33 (0.23–0.44) vs. 0.29 (0.17–0.45) 3 vs. 22 vs. 12 95.1%
Marsh vs. Marsh-Oberhuber classification 0.76 0.31 (0.18–0.47) vs. 0.34 (0.22–0.47) 13 vs. 18 95.7%
Prospective vs. retrospective design 0.86 0.34 (0.23–0.48) vs. 0.33 (0.20–0.47) 19 vs. 14 95.4%
Disappearance of villous atrophy
Children vs. adults 0.05# 0.74 (0.57–0.90) vs. 0.58 (0.45–0.71) 11 vs. 10 96.5%
Strict vs. non-strict/uncertain gluten-free diet 0.06# 0.72 (0.60–0.84) vs. 0.66 (0.59–0.72) 17 vs. 40 92.8%
Strict adherence with at least 12-month gluten-free diet vs. others 0.08# 0.77 (0.67–0.85) vs. 0.66 (0.60–0.72) 14 vs. 43 92.9%
Patients followed up for 12 months vs. others 0.03* 0.54 (0.41–0.67) vs. 0.67 (0.60–0.73) 12 vs. 45 97.5%
Length of gluten-free diet
(high vs. low vs. uncertain risk)
0.68 0.70 (0.56–0.81) vs. 0.65 (0.59–0.71) vs. 0.58 (0.34–0.79) 10 vs. 44 vs. 3 92.9%
Assessment of adherence
(high vs. low vs. uncertain risk)
0.60 0.59 (0.33–0.81) vs. 0.64 (0.56–0.71) vs. 0.69 (0.60–0.76) 4 vs. 27 vs. 26 92.9%
Initial histology
(high vs. low vs. uncertain risk)
0.09# 0.73 (0.64–0.80) vs. 0.61 (0.54–0.65) vs. 0.70 (0.58–0.80) 12 vs. 32 vs. 9 92.9%
Marsh vs. Marsh-Oberhuber classification 0.39 0.71 (0.59–0.81) vs. 0.65 (0.55–0.73) 12 vs. 21 94.6%
Prospective vs. retrospective design 0.13 0.63 (0.56;0.70) vs. 0.72 (0.63–0.79) 36 vs. 17 92.9%

* indicates statistical significance (p<0.05).

# indicates borderline significance (0.10>p≥0.05).